Background: The etiological diagnosis of chronic thrombocytopenia in children remains challenging and is often established by exclusion. In this article, we present the case of a patient in whom we used whole-exome sequencing (WES) to help identify the underlying cause and determine the appropriate treatment. Methods: Whole-exome sequencing was performed to clarify the genetic background of the disease. Based on the results, transmission electron microscopy (TEM) was also carried out to confirm or exclude the pathogenic role of the identified NBEAL2 gene variant and to assess the presence of gray platelet syndrome. Results: In this patient, despite the presence of the NBEAL2 gene variant, neither gray platelet syndrome nor a pathogenic role of the variant could be confirmed. However, the genetic findings identified by WES led to numerous additional investigations, causing a considerable burden on both the patient and the family. Conclusions: Our case highlights that WES testing, which is emerging in pediatric hematology practice, offers not only diagnostic advantages but also pitfalls. Whole-exome sequencing has recently emerged as a new diagnostic tool and has been available nationwide in pediatric hematology-oncology care in Hungary for just over two years. While personalized treatment strategies for benign hematologic diseases increasingly rely on high-throughput genetic testing, the clinical application of WES requires a cautious, critical evaluation of results. Despite the method’s promise, the heterogeneity of the findings underscores the need to interpret WES results carefully and to place them in a clinical context in every case.

Background/Objectives: Palliative sedation is among the most complex interventions in end-of-life care in pediatric oncology. Its interpretation is shaped not only by clinical criteria for refractory suffering but also by the differing perspectives of parents, children, and healthcare professionals. This qualitative study explored how bereaved parents experienced and retrospectively interpreted sedation in children who died of cancer following palliative sedation. Methods: We conducted semi-structured in-depth interviews with 17 parents from ten families recruited through a pediatric hospice network in Hungary. Interviews were analyzed using reflexive thematic analysis. Results: Parents assessed their children’s suffering through knowledge accumulated during everyday caregiving, which was more nuanced than standard pain-scale ratings. Their understanding of suffering also encompassed the loss of the child’s familiar lifeworld. Hope for recovery did not necessarily disappear during palliative care; it could coexist with hopes for more time, a continuing sense of purpose in caring for the child, or spiritual meaning. For many families, sedation was not experienced as a distinct decision point, particularly in children with brain tumors, where reduced consciousness and disease progression became intertwined. Persistent retrospective doubts were primarily associated with missed opportunities to say goodbye, death occurring sooner than anticipated, and inadequate symptom control. Conclusions: Communication about sedation should be understood as an ongoing, flexible process that addresses the anticipated course of events and opportunities for farewell. Bereavement support should also provide space for revisiting the decision retrospectively.